<DOC>
	<DOCNO>NCT02284568</DOCNO>
	<brief_summary>This Phase 2 study intend serve proof concept potential treatment laquinimod patient PPMS . The study also aim evaluate 2 dos laquinimod population .</brief_summary>
	<brief_title>A Phase 2 Clinical Study Subjects With Primary Progressive Multiple Sclerosis Assess Efficacy , Safety Tolerability Two Oral Doses Laquinimod Either 0.6 mg/Day 1.5mg/Day ( Experimental Drug ) Compared Placebo</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>1 . Patients must confirm documented PPMS diagnosis define 2010 Revised McDonald criterion 2 . Baseline magnetic resonance imaging ( MRI ) show lesion consistent PPMS either brain spinal cord 3 . Patients must Expanded Disability Status Scale ( EDSS ) score 3 6.5 , inclusive , screen baseline visit 4 . Documented evidence clinical disability progression 2 year prior screen . 5 . Functional System Score ( FSS ) &gt; equal 2 pyramidal system gait impairment due low extremity dysfunction 6 . Patients must 25 55 year age , inclusive 7 . Women childbearing potential must practice acceptable method birth control 30 day take study drug , 2 acceptable method birth control study duration 30 day last dose treatment administer . 8 . Patients must sign date write informed consent prior enter study . 9 . Patients must willing able comply protocol requirement duration study . 1 . Patients history multiple sclerosis ( MS ) exacerbation relapse , include episode optic neuritis . 2 . Progressive neurological disorder PPMS . 3 . Any MRI record show presence cervical cord compression . 4 . Baseline MRI show finding ( include lesion atypical PPMS ) may explain clinical sign symptom . 5 . Relevant history vitamin B12 deficiency . 6 . Positive human Tlymphotropic virus Type I II ( HTLVI/II ) serology . 7 . Use experimental investigational drug clinical study within 24 week prior baseline . Use currently market drug clinical study within 24 week prior baseline would exclusionary , provide exclusion criterion meet . 8 . Use immunosuppressive agent , cytotoxic agent , include cyclophosphamide azathioprine within 48 week prior baseline . 9 . Previous treatment fingolimod ( GILENYA® , Novartis ) , dimethyl fumarate ( TECFIDERA® , Biogen Idec Inc ) , glatiramer acetate ( COPAXONE® , Teva ) , interferonβ ( either 1a 1b ) , intravenous immunoglobulin , plasmapheresis within 8 week prior baseline . 10 . Use teriflunomide ( AUBAGIO® , Sanofi ) within 2 year prior baseline , except active washout ( either cholestyramine activated charcoal ) do 2 month prior baseline . 11 . Prior use monoclonal antibody ever , except : 1. natalizumab ( TYSABRI® , Biogen Idec Inc ) , give 24 week prior baseline AND patient John Cunningham ( JC ) virus antibody test negative ( per medical history ) 2. rituximab , ocrelizumab , ofatumumab , B cell count ( CD19 , per medical history ) high 80 cells/μL 12 . Use mitoxantrone ( NOVANTRONE® , Immunex ) within 5 year prior screen . Use mitoxantrone &gt; 5 year screen allow patient normal ejection fraction exceed total lifetime maximal dose . 13 . Previous use laquinimod . 14 . Chronic ( eg , 30 consecutive day monthly dose , intent MS disease modification ) systemic ( intravenous , intramuscular oral ) corticosteroid treatment within 8 week prior baseline . 15 . Previous use cladribine alemtuzumab ( LEMTRADA® , Sanofi ) . 16 . Previous total body irradiation total lymphoid irradiation . 17 . Previous stem cell treatment , cellbased treatment , bone marrow transplantation kind . 18 . Patients underwent endovascular treatment chronic cerebrospinal venous insufficiency ( CCSVI ) within 12 week prior baseline . 19 . Use moderate/strong inhibitor cytochrome P450 ( CYP ) 3A4 within 2 week prior baseline . 20 . Use inducer CYP3A4 within 2 week prior baseline . 21 . Pregnancy breastfeed . 22 . Serum level ≥3× upper limit normal range ( ULN ) either alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) screening . 23 . Serum direct bilirubin ≥2×ULN screening . 24 . Patients clinically significant unstable medical surgical condition ( opinion Investigator ) would preclude safe complete study participation , determine medical history , physical examination , electrocardiogram ( ECG ) , laboratory test chest Xray . 25 . A known history hypersensitivity gadolinium ( Gd ) . 26 . Glomerular filtration rate ( GFR ) &lt; equal 60 mL/min screen visit . 27 . Inability successfully undergo MRI scanning , include claustrophobia . 28 . Known drug hypersensitivity would preclude administration laquinimod , hypersensitivity mannitol , meglumine sodium stearyl fumarate .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>